Capsid protein inhibitors - Pipeline Insight, 2024

Capsid protein inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Capsid protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in Capsid protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Capsid protein inhibitors Understanding

Capsid protein inhibitors: Overview

A capsid is the protein shell of a virus, enclosing its genetic material. It consists of several oligomeric structural subunits made of protein called protomers. The capsid has three functions: 1) it protects the nucleic acid from digestion by enzymes, 2) contains special sites on its surface that allow the virion to attach to a host cell, and 3) provides proteins that enable the virion to penetrate the host cell membrane. Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing work in this area is contributing to an understanding of the molecular biology of HIV uncoating and maturation.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Capsid protein inhibitors R&D. The therapies under development are focused on novel approaches for Capsid protein inhibitors.

Capsid protein inhibitors Emerging Drugs Chapters

This segment of the Capsid protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Capsid protein inhibitors Emerging Drugs

• Lenacapavir: Gilead Sciences

Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection. Lenacapavir's multi-stage mechanism of action is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for the development of long-acting therapy options for people living with or at risk for HIV-1. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV-1 at multiple stages of its lifecycle and has no known cross resistance to other existing drug classes.

• RG7907: Roche

CpAM (RG7907) is an orally administered small molecule, class I hepatitis B virus (HBV) core protein allosteric modulator, that disrupts HBV nucleocapsids assembly and induces the depletion of functional core proteins, thereby effectively inhibiting HBV replication. A phase I clinical trial is evaluating RG7907 for the treatment of chronic hepatitis B infection.

Further product details are provided in the report……..

Capsid protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Capsid protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Capsid protein inhibitors

There are approx. 9+ key companies which are developing the Capsid protein inhibitors. The companies which have their Capsid protein inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Gilead Sciences.

• Phases

DelveInsight’s report covers around 9+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Capsid protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Capsid protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Capsid protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Capsid protein inhibitors drugs.

Capsid protein inhibitors Report Insights

• Capsid protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Capsid protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Capsid protein inhibitors drugs?
• How many Capsid protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Capsid protein inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Capsid protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Capsid protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gilead Sciences
• Roche
• Janssen Sciences Ireland
• GlaxoSmithKline
• ViiV Healthcare
• Protheragen
• Arbutus Biopharma
• Aviragen Therapeutics
• Aligos Therapeutics
• Alios BioPharma

Key Products

• Lenacapavir
• RG 7907
• Bersacapavir
• GSK 3640254
• Combinectin
• GS CA1
• ARB-168786
• AB 836
• BTA-798
• ALG 000184
• JNJ 440